Used in pharmaceutical research as a potent and selective inhibitor of ALK (anaplastic lymphoma kinase), showing promise in the development of targeted cancer therapies, particularly for non-small cell lung cancer (NSCLC) and other ALK-driven tumors. Its structure enables high binding affinity and improved pharmacokinetic properties, making it suitable for oral administration in preclinical studies. Also investigated for overcoming resistance mutations in ALK, including the common G1202R mutation, where traditional inhibitors lose efficacy. Currently utilized in experimental models to evaluate tumor growth suppression and central nervous system penetration for potential treatment of brain metastases.